levofloxacin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Maxillary Sinusitis

Conditions

Maxillary Sinusitis

Trial Timeline

Nov 1, 2003 → Jun 1, 2005

NCT ID

NCT00236652

About levofloxacin

levofloxacin is a phase 3 stage product being developed by Johnson & Johnson for Maxillary Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00236652. Target conditions include Maxillary Sinusitis.

What happened to similar drugs?

2 of 4 similar drugs in Maxillary Sinusitis were approved

Approved (2) Terminated (1) Active (2)

🔄azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacinPfizerPhase 3

🔄TelithromycinSanofiPhase 3

✅Azithromycin + TelithromycinSanofiApproved

✅Avelox (Moxifloxacin, BAY12-8039)BayerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002249	Phase 1	Completed	—	—	HIV Infections
NCT00210886	Phase 3	Completed	Oct 1, 2004	Apr 1, 2006	Urinary Tract Infections
NCT00645437	Phase 1	Completed	Oct 1, 2004	Apr 1, 2006	Renal Diseases
NCT00236652	Phase 3	Completed	Nov 1, 2003	Jun 1, 2005	Maxillary Sinusitis
NCT00044473	Phase 3	Completed	Nov 1, 2002	Jul 1, 2003	Otitis Media
NCT00236522	Phase 3	Completed	Oct 1, 2002	Apr 1, 2004	Sinusitis
NCT00034736	Phase 3	Completed	Aug 1, 2002	Jun 1, 2004	Pneumonia
NCT00236821	Phase 3	Completed	Mar 1, 2001	Jun 1, 2002	Pneumonia
NCT00236808	Phase 3	Completed	May 1, 2000	Nov 1, 2001	Prostatitis
NCT00249197	Phase 3	Completed	Jan 1, 1997	Jul 1, 1998	Skin Diseases, Bacterial
NCT00269932	Phase 3	Completed	Aug 1, 1993	May 1, 1994	Bronchitis, Chronic
NCT00249210	Phase 3	Completed	Aug 1, 1993	Jul 1, 1994	Sinusitis
NCT00258089	Phase 3	Completed	Jun 1, 1993	Jan 1, 1995	Urinary Tract Infections
NCT00258102	Phase 3	Completed	Jan 1, 1993	Jan 1, 1995	Urinary Tract Infections
NCT00257062	Phase 3	Completed	Jan 1, 1993	Apr 1, 1994	Skin Diseases, Infectious
NCT00257036	Phase 2/3	Completed	Jul 1, 1991	Feb 1, 1993	Skin Diseases, Infectious
NCT00257049	Phase 2/3	Completed	Jan 1, 1984	Jan 1, 1995	Pneumonia
NCT00257140	Phase 2/3	Completed	Jun 1, 1931	Jul 1, 1994	Bronchitis

Competing Products

5 competing products in Maxillary Sinusitis

See all competitors

Product	Company	Stage	Hype Score
Azithromycin SR + Amoxiclav 1000 mg	Pfizer	Pre-clinical	26
azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin	Pfizer	Phase 3	40
Telithromycin	Sanofi	Phase 3	40
Azithromycin + Telithromycin	Sanofi	Approved	35
Avelox (Moxifloxacin, BAY12-8039)	Bayer	Approved	40